StockData

Revvity vs 10x Genomics

RVTY and TXG side by side, both in laboratory apparatus and analytical, optical, measuring, and controlling instruments. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How RVTY and TXG compare

Revvity is the larger company, worth 2.2 times as much as 10x Genomics ($16.5B against $7.3B).

Revvity grew revenue faster over the last twelve months (4.1% versus −3.6% for 10x Genomics).

Revvity keeps more of each dollar of sales as profit, with a net margin of 8.2% compared with −10.8% at 10x Genomics.

Revvity pays a dividend yielding 0.14%; 10x Genomics does not pay one.

Revvity scores higher on the StockData Score (11 against 9 for 10x Genomics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricRVTYTXG
Size and price
Market cap$16.5B$7.3B
Share price$147.79$56.30
Change, 1 year59.4%254%
Change, 5 years−19.3%−62.2%
Beta (5Y)1.101.67
Employees11K1,178
StockData Score
Total score11 (better)9
Valuation score1 (better)0
Growth score12 (better)
Performance score2 (better)1
Health score36 (better)
Dividend score4 (better)0
Valuation
P/E70.4×–
P/S5.7× (better)11.9×
P/B2.3× (better)8.8×
EV/EBITDA24.2×–
P/FCF29.5× (better)78.2×
FCF yield3.4% (better)1.3%
Fair value$104.02$26.65
Margin of safety−42.1% (better)−111%
Growth
Revenue growth (TTM)4.1% (better)−3.6%
Revenue growth, 5Y average1.4%16.6% (better)
Net income growth (TTM)−16.7%–
EPS growth (TTM)−11.0%–
EPS growth, 5Y average−20.4%–
Profitability
Gross margin–71.9%
Operating margin12.3% (better)−11.7%
Net margin8.2% (better)−10.8%
FCF margin19.2% (better)15.2%
Return on equity3.2% (better)−8.3%
Return on invested capital3.4% (better)−20.2%
Financial health
Debt / equity0.44 (better)0.00
Net debt / EBITDA2.83–
Interest coverage3.8×–
Current ratio1.805.12 (better)
Altman Z-score3.2118.51 (better)
Piotroski F-score66
Dividends and buybacks
Dividend yield0.14%–
Payout ratio13.4%–
Years of dividend growth0–
Dividend growth, 5Y average0.00%–
Buyback yield2.9%–
Shareholder yield3.0% (better)0.00%
Ownership
Held by institutions102%98.7%
Held by insiders0.46%4.2%
Insider net buying, 12 months−$6.0M (better)−$18.2M
Superinvestors holding–1
Short interest, % of float5.9%10.0%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.